Form 4: Gossamer Bio CMO Granted Performance Stock Units

Gossamer Bio's Chief Medical Officer, Richard Aranda, was granted 162,500 performance stock units, vesting upon key milestones related to seralutinib or a change in control.

Summary

• Richard Aranda, Chief Medical Officer of Gossamer Bio, Inc. (GOSS), was granted 162,500 shares of common stock as a performance stock unit award on October 1, 2025.
• The units will vest in full upon the earlier of New Drug Application (NDA) approval for seralutinib or a change in control, provided these events occur on or prior to the fourth anniversary of the grant date.
• Vesting is also contingent on Mr. Aranda's continuous service to the company.
• Following this grant, Mr. Aranda directly holds 369,356 shares of common stock and indirectly holds 2,539 shares through a family trust.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The grant of performance stock units to the Chief Medical Officer, tied to the critical milestone of seralutinib NDA approval or a change in control, indicates strong alignment of executive incentives with significant value-creation events for the company. This structure motivates leadership towards achieving key strategic objectives.

Positives

• The grant of performance stock units aligns executive incentives with key corporate milestones, specifically the potential New Drug Application (NDA) approval for seralutinib.
• Vesting conditions tie executive compensation directly to significant value-creation events for shareholders, fostering strong alignment between management and investor interests.

Risks

• Vesting of the performance stock units is contingent on the successful approval of seralutinib's New Drug Application (NDA), which is subject to regulatory uncertainties and clinical trial outcomes.
• The alternative vesting condition, a change in control, introduces an element of uncertainty regarding the company's future ownership structure and strategic direction.

Future Outlook

The vesting conditions for the performance stock units highlight the company's strategic focus on achieving New Drug Application (NDA) approval for seralutinib within the next four years, or a potential change in control, as key drivers for executive compensation and shareholder value.

Industry Context

In the biotechnology and pharmaceutical industry, performance-based equity awards are a common practice for executive compensation, particularly when tied to critical regulatory milestones like New Drug Application (NDA) approvals, which are significant value drivers for drug development companies.

Comparison to Industry Standards

• Performance-based equity grants tied to specific drug development milestones (e.g., NDA approval) are a standard practice in the biopharmaceutical industry to incentivize executives and align their interests with long-term shareholder value creation.
• Many biotech companies, such as Moderna (MRNA) or BioNTech (BNTX), utilize similar incentive structures for their R&D and medical leadership, linking compensation to clinical trial success and regulatory achievements.
• The grant of 162,500 units at a $0 price is typical for a performance stock unit award, where the value is realized upon vesting based on achieving predefined conditions.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact through increased executive incentive to achieve seralutinib NDA approval, which could significantly increase company value.
• Customers/Patients: Successful NDA approval for seralutinib would make a new drug available to patients, addressing unmet medical needs.

Next Steps

• Continued development and regulatory submission process for seralutinib.
• Monitoring for potential New Drug Application (NDA) approval for seralutinib.
• Monitoring for any potential change in control events for Gossamer Bio.

Key Dates

Recommendation

This Form 4 indicates a significant performance-based equity grant to a key executive, aligning their compensation with critical drug development milestones. While this is a positive signal for executive incentive alignment and confidence in seralutinib, it is a single transaction disclosure and does not provide comprehensive financial or operational data to warrant a stronger recommendation. Investors should hold and monitor the progress of seralutinib and other company developments.

Keywords

Gossamer Bio, GOSS, Richard Aranda, Chief Medical Officer, performance stock units, PSU, equity grant, insider transaction, SEC Form 4, seralutinib, NDA approval, Rule 10b5-1